Journal profile · PHARMACOLOGY & PHARMACY
Recent Advances in Inflammation & Allergy Drug Discovery
ISSN 2772-2716 · eISSN 2772-2708 · Bentham
Recent Advances in Inflammation & Allergy Drug Discovery: CAS Zone 4 · Medicine (2025 upgraded edition); subscription journal; median 105 days to acceptance (72 articles, last 24 months); 26 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Recent Advances in Inflammation & Allergy Drug Discovery is published by Bentham and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory mediators and NSAID effects, Dermatology and Skin Diseases and Natural Compounds in Disease Treatment, together about 21.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory mediators and NSAID effectsMedicine7.2%
- Dermatology and Skin DiseasesMedicine7.2%
- Natural Compounds in Disease TreatmentMedicine6.7%
- Asthma and respiratory diseasesMedicine5.7%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics5.7%
- COVID-19 Clinical Research StudiesMedicine4.6%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology4.6%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology (medical) | Q3 | 188/278 | 32nd |
| Immunology and Allergy | Q4 | 182/234 | 22nd |
| Drug Discovery | Q4 | 128/161 | 20th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 2LetPub ·
- SJR 2026-06
- 0.39LetPub ·
- SNIP 2026-06
- 0.64LetPub ·
- h-index
- 9OpenAlex ·
- i10-index
- 8OpenAlex ·
- 2-year mean citedness
- 0.89OpenAlex ·
- Self-citation rate
- 6.7%LetPub ·
- Share of gold OA articles
- 4.94%LetPub ·
Volume
- Articles per year
- 27LetPub ·
Articles by year OpenAlex count · 181 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 50 | 0 | 99 |
| 2025 | 26 | 0 | 133 |
| 2024 | 43 | 4 | 75 |
| 2023 | 21 | 2 | 46 |
| 2022 | 36 | 2 | 17 |
| 2021 | 5 | 0 | 1 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
105 daysMedian, submission to acceptance · P25–P75 77 days – 130 days
- Acceptance to online
- median 114 days (47 articles)
- Submission to online
- median 212 days
- Sample
- 72 articles with submission and acceptance dates (100 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham
- ISSN
- 2772-2716
- Electronic ISSN
- 2772-2708
FAQ
Frequently asked questions about Recent Advances in Inflammation & Allergy Drug Discovery
What CAS zone is Recent Advances in Inflammation & Allergy Drug Discovery in?
In the 2025 upgraded edition of the CAS Journal Ranking, Recent Advances in Inflammation & Allergy Drug Discovery is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Recent Advances in Inflammation & Allergy Drug Discovery?
Based on the dates recorded on 72 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 105 days (interquartile range 77–130 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Recent Advances in Inflammation & Allergy Drug Discovery?
According to LetPub and DOAJ records, Recent Advances in Inflammation & Allergy Drug Discovery is indexed in ESCI and Scopus.
Is Recent Advances in Inflammation & Allergy Drug Discovery open access, and what is the APC?
Recent Advances in Inflammation & Allergy Drug Discovery is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .